Showing results (31-40 of 49) with videos related to

Sort By:
Pageof 5
Oncoimmunology|September 13, 2021
In vivo trafficking of a tumor-targeting IgE antibody: molecular imaging demonstrates rapid hepatobiliary clearance compared to IgG counterpartFrancis Man, Alexander Koers, Panagiotis Karagiannis, et al.
Scientific Reports|June 3, 2020
Rapid conjugation of antibodies to toxins to select candidates for the development of anticancer Antibody-Drug Conjugates (ADCs)Ricarda M Hoffmann, Silvia Mele, Anthony Cheung, et al.
Science Signaling|April 6, 2017
The conformational state of hERG1 channels determines integrin association, downstream signaling, and cancer progressionAndrea Becchetti, Silvia Crescioli, Francesca Zanieri, et al.
Frontiers in Immunology|September 30, 2017
Functionally Active Fc Mutant Antibodies Recognizing Cancer Antigens Generated Rapidly at High YieldsKristina M Ilieva, Judit Fazekas-Singer, Daniela Y Achkova, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 23, 2014
hERG1 channels regulate VEGF-A secretion in human gastric cancer: clinicopathological correlations and therapeutical implicationsOlivia Crociani, Elena Lastraioli, Luca Boni, et al.
Scientific Reports|July 15, 2016
IgG subclass switching and clonal expansion in cutaneous melanoma and normal skinLouise Saul, Kristina M Ilieva, Heather J Bax, et al.
Journal for Immunotherapy of Cancer|June 11, 2021
Immunotherapy using IgE or CAR T cells for cancers expressing the tumor antigen SLC3A2Giulia Pellizzari, Olivier Martinez, Silvia Crescioli, et al.
Frontiers in Immunology|February 11, 2021
B Cells in Patients With Melanoma: Implications for Treatment With Checkpoint Inhibitor AntibodiesZena N Willsmore, Robert J Harris, Silvia Crescioli, et al.
European Journal of Immunology|January 15, 2021
Combined anti-PD-1 and anti-CTLA-4 checkpoint blockade: Treatment of melanoma and immune mechanisms of actionZena N Willsmore, Ben G T Coumbe, Silvia Crescioli, et al.
NPJ Precision Oncology|March 7, 2026
An antibody-drug conjugate designed through clone and isotype selection restricts the growth of CSPG4-expressing triple-negative breast cancerBenjamina Esapa, Yi Liu, Alicia M Chenoweth, et al.
Pageof 5